Barclays lowered the firm’s price target on Celldex (CLDX) to $21 from $25 and keeps an Underweight rating on the shares following the Q3 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex’s Promising Pipeline and Strategic Advancements Justify Buy Rating
- Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress
- Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position
- Celldex reports Q3 EPS ($1.01), consensus (89c)
- Celldex appoints Lawver as Chief Commercial Officer